UK's first professor of teenage and young adult cancer appointed in Manchester

October 24, 2005

Teenage Cancer Trust (TCT) has announced that Professor Tim Eden has been appointed to the UK's first TCT Teenage and Young Adult Cancer Chair, based across The University of Manchester, the Christie Hospital and Central Manchester & Manchester Children's University Hospitals NHS Trust. The appointment will put Manchester and Britain at the forefront of research into a disease that affects over 2,200 teenagers every year, and comes in the wake of National Institute for Clinical Excellence guidelines on young people's cancers calling for "age-appropriate facilities, provided as locally as possible".

Cancer in teenagers and young adults is on the increase. Incidence rates over the last 30 years have grown by 50% - an average annual rise of 1.2% - and cancer is the most common cause of non-accidental death in teenagers and young adults in the UK.

Improvements in survival rates have been much less than in children and many older adults in the last 20 years, and the number of patients entered into clinical trials is also much lower. This lack of research means very little is known about why teenagers get cancer.

Now Teenage Cancer Trust has invested £2.5m over 10 years to fund the Professor and his team, who will act as a national research lead and voice on teenage cancer issues as well as increasing research, international collaboration and clinical trial opportunities.

Professor Eden's clinical and academic base has been at both the Christie Hospital and Central Manchester and Manchester Children's University Hospitals NHS Trust since 1994, and he has worked in the Christie's dedicated 13-bed Teenage Cancer Trust Unit since its founding in 1998. Focusing on 15-24 year olds, his research activity has included the causes, distribution and control of cancer, explorations of new and targeted therapies and psycho-social factors, and he is currently chair of the International Society of Paediatric Oncology (SIOP).

Professor Eden said: "Despite great advances in understanding and treating childhood cancer over the last 30 years and the recent focus on recruiting older adults into clinical trials, there has been relatively little progress on cancer in adolescence and early adult life. Teenage Cancer Trust exists to improve recognition and understanding of these cancers, and their support will also help us enhance treatment options, improve entry into clinical trials and increase quality of life and survival rates.

"By working closely with these patients we can recognise their needs and help improve their treatment outcomes. The challenges are huge but the rewards will be immense."

Myrna Whiteson MBE, Chairman of Teenage Cancer Trust said: "The appointment of a TCT Teenage and Young Adult Cancer Chair highlights the growing importance of this field of medicine. It provides a focus to extend the parameters of knowledge within the field, and will hopefully lead to improved outcomes. We know it will result in a better quality of life for many thousands of teenagers."

Professor Andy Garner, Dean of the Medical School at The University of Manchester, said: "I am delighted that Manchester has been chosen to host the TCT Teenage and Young Adult Cancer Chair, on the basis of its research strengths in the causes of and treatments for cancer. The University's medical research excellence is internationally renowned, and we are eager to apply it to this previously under-resourced field."

Professor Joan Higgins, Chair of the Christie Hospital, said: "This is an important appointment and we are delighted that Professor Tim Eden has been chosen for this prestigious post. Professor Eden has done an outstanding job in heading up our teenage cancer unit and we are very proud of the care we provide to young cancer patients. His expertise and dedication is truly admirable and he will, no doubt, excel in this new role."

Professor Mike Richards, National Cancer Director, said: "I strongly applaud the vision of Teenage Cancer Trust in establishing this first Chair in adolescent cancer, and congratulate Professor Eden, The University of Manchester, the Christie Hospital and Central Manchester and Manchester Children's University Hospitals on being chosen to host it. The establishment of a dedicated research team in Manchester will stimulate much needed research into cancers affecting adolescents."
Teenage Cancer Trust focuses on the needs of teenagers and young adults with cancer, leukaemia, Hodgkin's and related diseases by providing specialist teenage units in NHS hospitals. The units are dedicated areas for teenage patients, who are involved in their concept and creation. Medical facilities on the units are second-to-none and they are colourful and vibrant environments, equipped with computers, TVs, game consoles - places where friends and family feel comfortable to visit.

To date, TCT has built eight units located in London (on two sites), Leeds, Liverpool, Birmingham, Sheffield, Newcastle and Manchester and is in discussion with an additional 14 trusts. It is anticipated that the concentration of medical expertise within these units can improve chances of recovery by 15%. Units cost an average £1.5 million each to build and TCT must complete at least 20 units in the UK so that every teenager and young adult with cancer in the UK has access to these facilities. Visit for more information.

Teenage Cancer Trust

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to